Raffaele Migliore

699 total citations
13 papers, 541 citations indexed

About

Raffaele Migliore is a scholar working on Psychiatry and Mental health, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Raffaele Migliore has authored 13 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 3 papers in Pharmacology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Raffaele Migliore's work include Schizophrenia research and treatment (8 papers), Bipolar Disorder and Treatment (5 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers). Raffaele Migliore is often cited by papers focused on Schizophrenia research and treatment (8 papers), Bipolar Disorder and Treatment (5 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers). Raffaele Migliore collaborates with scholars based in United States, Hungary and India. Raffaele Migliore's co-authors include Suresh Durgam, György Németh, I. Laszlovszky, Adam Ruth, Anju Starace, Kaifeng Lu, Dayong Li, Andrew J. Cutler, Herbert Y. Meltzer and Yao Wang and has published in prestigious journals such as Psychopharmacology, Schizophrenia Research and The Journal of Clinical Psychiatry.

In The Last Decade

Raffaele Migliore

13 papers receiving 530 citations

Peers

Countries citing papers authored by Raffaele Migliore

Since Specialization

Citations

This map shows the geographic impact of Raffaele Migliore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raffaele Migliore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raffaele Migliore more than expected).

Fields of papers citing papers by Raffaele Migliore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raffaele Migliore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raffaele Migliore. The network helps show where Raffaele Migliore may publish in the future.

Co-authorship network of co-authors of Raffaele Migliore

This figure shows the co-authorship network connecting the top 25 collaborators of Raffaele Migliore. A scholar is included among the top collaborators of Raffaele Migliore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raffaele Migliore. Raffaele Migliore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 2025 ·Pituitary ·Sabrina Chiloiro, Antonella Giampietro, Raffaele Migliore, (unknown), (unknown), (unknown), Pier Paolo Mattogno, Rosalinda Calandrelli, Tommaso Tartaglione, Liverana Lauretti, Mario Rigante, Marco Gessi, Simona Gaudino, Laura De Marinis, Antonio Bianchi, Francesco Doglietto, Alfredo Pontecorvi	1
2	Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study 2019 ·Depression and Anxiety ·Suresh Durgam, Changzheng Chen, Raffaele Migliore, (unknown), Michael E. Thase	7
3	Relapse prevention in adults with major depressive disorder treated with vilazodone 2018 ·International Clinical Psychopharmacology ·Suresh Durgam, Carl Gommoll, Raffaele Migliore, Changzheng Chen, Cheng‐Tao Chang, (unknown), Michael E. Thase	11
4	A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder 2018 ·Pediatric Drugs ·Suresh Durgam, Changzheng Chen, Raffaele Migliore, (unknown), John Edwards, Robert L. Findling	23
5	Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study 2017 ·CNS Spectrums ·Andrew J. Cutler, Suresh Durgam, Yao Wang, Raffaele Migliore, Kaifeng Lu, I. Laszlovszky, György Németh	47
6	Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study 2016 ·Psychopharmacology ·Suresh Durgam, William M. Greenberg, Dayong Li, Kaifeng Lu, I. Laszlovszky, György Németh, Raffaele Migliore, (unknown)	44
7	Cariprazine in Acute Exacerbation of Schizophrenia 2015 ·The Journal of Clinical Psychiatry ·Suresh Durgam, Andrew J. Cutler, Kaifeng Lu, Raffaele Migliore, Adam Ruth, I. Laszlovszky, György Németh, Herbert Y. Meltzer	137
8	An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial 2014 ·Schizophrenia Research ·Suresh Durgam, Anju Starace, Dayong Li, Raffaele Migliore, Adam Ruth, György Németh, I. Laszlovszky	147
9	Poster #M227 SAFETY AND TOLERABILITY OF CARIPRAZINE IN THE LONG-TERM TREATMENT OF SCHIZOPHRENIA 2014 ·Schizophrenia Research ·Suresh Durgam, Andrew J. Cutler, Yao Wang, Raffaele Migliore, Kaifeng Lu, I. Laszlovszky, Krisztián Nagy	2
10	The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial 2014 ·Bipolar Disorders ·Suresh Durgam, Anju Starace, (unknown), Raffaele Migliore, Adam Ruth, György Németh, I. Laszlovszky	96
11	P.3.d.033 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial 2013 ·European Neuropsychopharmacology ·J.A. Lieberman, Andrew J. Cutler, Shaogui Wan, Raffaele Migliore, Adam Ruth, I. Laszlovszky, György Németh, Suresh Durgam	7
12	The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia 2011 ·European Psychiatry ·(unknown), (unknown), Raffaele Migliore, P. Werner, György Németh, (unknown)	11
13	P.3.c.062 The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia 2010 ·European Neuropsychopharmacology ·(unknown), (unknown), Raffaele Migliore, P. Werner, György Németh, I. Laszlovszky	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact